
|Articles|June 20, 2019
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
Author(s)Adi Diab, MD
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Advertisement
Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
5


















































